Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it will convene a Tissue Diagnostics Patient Safety Advisory Board on February 27 at its headquarters in Tucson, Arizona.
The board, comprised of experts in anatomic pathology from leading healthcare institutions around the globe, will examine laboratory-based patient safety issues and work towards a consensus on how to advance the standard of care for patients. They will focus on such matters as:
- The current state of patient safety in anatomic pathology , including key unmet needs
- Perspectives on how additional industry guidelines could improve patient care
- Technology’s role in improving quality and the patient safety standard of care
Dr. Eslie Dennis, Vice President of Scientific Affairs for Ventana and chair of the advisory board, noted, “Patient safety is a priority in anatomic pathology laboratories worldwide; still, a great deal remains to be done. In the United States, eight percent of tissue slides are cross-contaminated in the traditional H&E staining process and more than one in 100 are misidentified due to human error. With the help of our advisory board, we hope to identify new opportunities and processes to achieve the greatest level of patient safety possible.”
“Healthcare workers have long invested in practices and technologies to reduce the risk of errors near to the patient, but anatomic pathology laboratories have often been underfunded to address such concerns. Bringing together this renowned group of experts will stimulate further attention on this issue in a critical area of diagnostics,” says Adrian Ralph, Vice President of Primary Staining for Ventana.
Ventana Medical Systems, Inc. (“VMSI”) (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company’s intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of “companion diagnostics” to identify the patients most likely to respond favorably to specific therapies.
VENTANA and the VENTANA logo are trademarks of Roche.CONTACT: Jacqueline Bucher Sr. Director, Corp. Communications Ventana Medical Systems, Inc. Tel 520.877.7288 o Tel 520.468.9145 m Jacquie.firstname.lastname@example.org
SOURCE Ventana Medical Systems, Inc.